The CRC Blueprint

My scientific approach to my own cancer – shared with you.

United States

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Phase 2 · randomised · 110 people · 3 sites in 2 countries · Recruiting now

August 7, 2026
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Phase 3 · randomised · 400 people · 3 sites in United States · Recruiting now

August 7, 2026
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Phase 2 · randomised · 150 people · 5 sites in 3 countries · Recruiting now

August 7, 2026
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers

Phase 2 · 220 people · 55 sites in 13 countries · Recruiting now

August 7, 2026
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Phase 2 · randomised · 1,109 people · 47 sites in 8 countries · Recruiting now

August 7, 2026
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Phase 2 · randomised · 86 people · 286 sites in 2 countries · Running, not taking new patients

August 7, 2026
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Phase 2 · randomised · 66 people · 1 site in United States · Recruiting now

August 7, 2026
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Phase 2 · 60 people · 1 site in United States · Recruiting now

August 7, 2026
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

Phase 2 · 100 people · 11 sites in United States · Recruiting now

August 7, 2026
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Phase 2 · randomised · 327 people · 86 sites in 7 countries · Running, not taking new patients

August 7, 2026